image: The approved drug cediranib suppressed the activity of the HDR DNA repair pathway (green) in ovarian cancer cells. This material relates to a paper that appeared in the May 15, 2019, issue of Science Translational Medicine, published by AAAS. The paper, by A.R. Kaplan at Yale University School of Medicine in New Haven, CT; and colleagues was titled, "Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51." view more
Credit: [Credit: A.R. Kaplan et al., Science Translational Medicine (2019)]